Pyxis Oncology, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-15 meeting.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following vote: For Against Abstain Broker Non-Votes 46,203,257 1,076,997 21,781 —”
Shareholder Votes
Pyxis Oncology, Inc. shareholders approved Election of Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger as Class II Directors at the 2026-06-15 meeting.
“Proposal One: Election of Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger as Class II Directors Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger were elected to serve as Class II directors to hold office until the Company’s 2029 Annual Meeting of Stockholders and until the election and qualification of their successors. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Mr. Thomas Civik 27,341,415 1,981,857 17,978,763 Dr. Freda Lewis-Hall, M.D. 19,188,755 10,134,517 17,978,763 Mr. Michael A. Metzger 26,521,575 2,801,697 17,978,763”
Earnings Releases
Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 14, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and provided a corporate update.”
Lara Sullivan resigned as Director at Pyxis Oncology, Inc..
“Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.”
Lara Sullivan departed as Chief Executive Officer at Pyxis Oncology, Inc..
“On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.”
Lara S. Sullivan changed role as Chief Medical Officer at Pyxis Oncology, Inc..
“Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.”
Ken Kobayashi departed as Chief Medical Officer at Pyxis Oncology, Inc..
“On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.”
Michael A. Metzger was appointed as Director at Pyxis Oncology, Inc..
“On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).”
Earnings Releases
Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update.”
Earnings Releases
Pyxis Oncology, Inc. reported the full year ended December 31, 2023 results: net income $73.8 million, or ($1.85) per common share.
“Net loss was $73.8 million, or ($1.85) per common share, for the year ended December 31, 2023, compared to $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022.”
Santhosh Palani, Ph.D., CFA was appointed as Director at Pyxis Oncology, Inc..
“On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA ® , to its Board of Directors (the “Board”).”
Material Agreements
Pyxis Oncology, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-02-26).
“On February 26, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Pre-Funded Warrant Shares held by the Purchasers (the “Registrable Securities”).”
Material Agreements
Pyxis Oncology, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $50 million (effective 2024-02-26).
“On February 26, 2024, Pyxis Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).”
Ken Kobayashi was appointed as Chief Medical Officer at Pyxis Oncology, Inc..
“On November 28, 2023, Pyxis Oncology, Inc. (the “Company”) announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, effective as of November 27, 2023 (the “Effective Date”).”
Earnings Releases
Pyxis Oncology, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 7, 2023, Pyxis Oncology, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2023”
M&A Transactions
Pyxis Oncology, Inc. completed an acquisition involving Apexigen, Inc. for all-stock transaction valued at approximately $10.7 million (closed 2023-08-23).
“clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million. The combined company is positioned at the forefront of ADC innovation with a platform that now includes four key components: novel humanized antibody generation capabilities, an”
Jakob Dupont was appointed as Director at Pyxis Oncology, Inc..
“On August 23, 2023, effective as of the Effective Time, Jakob Dupont, M.D., a former director of Apexigen, was appointed to the Board as a Class III director and his term will expire at the annual meeting of stockholders to be held in 2024.”
Earnings Releases
Pyxis Oncology, Inc. reported the quarter ended June 30, 2023 results: net income $15.9 million, EPS $0.41 per common share.
“Net loss was $15.9 million, or $0.41 per common share, for the three months ended June 30, 2023”
Jakob Dupont was appointed as Director at Pyxis Oncology, Inc..
“the Board also approved on a prospective basis the appointment of Jakob Dupont, M.D. as a director of the Company to fill the vacancy created by that action.”
Shareholder Votes
Pyxis Oncology, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
“The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote: For Against Abstain Broker Non-Votes 27,404,246 80,518 29,653 —”
Shareholder Votes
Pyxis Oncology, Inc. shareholders approved Election of Freda Lewis-Hall, M.D. and Thomas Civik as Class II Directors at the 2023-06-13 meeting.
“Freda Lewis-Hall, M.D. and Thomas Civik were elected to serve as Class II directors to hold office until the Company’s 2026 Annual Meeting of Stockholders and until the election and qualification of their successors. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Freda Lewis-Hall, M.D. 13,597,586 3,416,105 10,500,726 Thomas Civik 13,452,770 3,560,921 10,500,726”
Shareholder Votes
Pyxis Oncology, Inc. shareholders approved Election of Rachel Humphrey, M.D. as Class I Director at the 2023-06-13 meeting.
“Rachel Humphrey, M.D. was elected to serve as a Class I director to hold office until the Company’s 2025 Annual Meeting of Stockholders and until the election and qualification of her successor. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Rachel Humphrey, M.D. 13,536,830 3,476,861 10,500,726”
Material Agreements
Pyxis Oncology, Inc. entered into Merger Agreement with Apexigen, Inc. (effective 2023-05-23).
“On May 23, 2023, Pyxis Oncology, Inc., a Delaware corporation (“Pyxis Oncology” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Apexigen, Inc., a Delaware corporation (“Apexigen”)”
Jay Feingold resigned as Chief Medical Officer at Pyxis Oncology, Inc..
“On May 24, 2023, the Company announced that Jay Feingold, M.D., Ph.D., will be stepping down from his position as the Company's Chief Medical Officer to pursue other opportunities.”
Earnings Releases
Pyxis Oncology, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023, EPS $0.54 per common share.
“Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023”
Earnings Releases
Pyxis Oncology, Inc. reported the full year ended December 31, 2022 results: net income $120.7 million, EPS ($3.65) per common share.
“Net loss was $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022, compared to $76.0 million, or ($8.95) per common share, for the year ended December 31, 2021.”
Pamela Connealy changed role as Chief Financial Officer and Chief Operating Officer at Pyxis Oncology, Inc..
“On March 22, 2023, the Company announced that Pamela Connealy, Chief Financial Officer, has been promoted to the newly created role of Chief Financial Officer and Chief Operating Officer.”
Earnings Releases
Pyxis Oncology, Inc. reported three months ended September 30, 2022 results: net income $27.7 million, EPS $(0.85) per common share.
“Net loss was $27.7 million, or $(0.85) per common share, for the three months ended September 30, 2022”
Rachel Humphrey was appointed as Director at Pyxis Oncology, Inc..
“On August 11, 2022, Pyxis Oncology, Inc. appointed Rachel Humphrey, M.D., to its Board of Directors and to serve on the Board’s Nominating and Corporate Governance Committee and Compensation Committee.”
Jitendra Wadhane was appointed as Chief Accounting Officer at Pyxis Oncology, Inc..
“On August 3, 2022, Jitendra Wadhane, age 42, was appointed as Chief Accounting Officer and to serve as Principal Accounting Officer of Pyxis Oncology, Inc. (the “Company”).”
Mark Chin resigned as Director at Pyxis Oncology, Inc..
“On April 12, 2022, Mark Chin resigned from his position as a director of the board of directors (the “Board”) of the Company, effective immediately.”
Ronald Herbst resigned as Chief Scientific Officer at Pyxis Oncology, Inc..
“On April 8, 2022, Ronald Herbst, Ph.D. resigned from his position with Pyxis Oncology, Inc. (the “Company”) as Chief Scientific Officer, effective on April 12, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.